The Arizona Health Care Cost Containment System (AHCCCS), in partnership with Crisis Response Network, announces a new COVID-19 appointment and transportation navigation program for Medicaid members. Now, Medicaid members who need assistance scheduling a COVID-19 vaccine appointment, as well as transportation to and from that appointment, can call 1-844-542-8201, 8 a.m. to 5 p.m., seven days a week.Continue reading
Author Archive: AZBio
Calviri Appoints Marc Wolff Chief Executive Officer
PHOENIX–(BUSINESS WIRE)–Calviri announces the appointment of Marc Wolff as Chief Executive Officer. Founder and current CEO, Stephen Albert Johnston, will continue to serve as Chairman of the Board of Directors and Founding CEO.Continue reading
C-Path’s Alzheimer’s Disease Consortium Expands Data Repository
New patient-level data will facilitate more efficient clinical trial design
OncoMyx Presents at AACR First Data Showing Multi-Armed Myxoma Virotherapy Can Modulate Anti-Tumor Immune Response
OncoMyx’s multi-armed myxoma virotherapy upregulates genes associated with immune response and shows modulation of the immune response to favor anti-tumor immunity
vMYX-hIL-12/Dec produces functional protein (hIL-12) from transgenes in vivo and in a dose and time responsive in vitro and has demonstrated anti-tumor efficacy in a xenograft human lung cancer model
Quantitative systems pharmacology modeling suggests IV administration of multi-armed myxoma virotherapy to fall within known safety margins at the planned doses of oncolytic immunotherapiesContinue reading
COVID-19 Testing Comes to Arizona’s Schools
Arizona’s leading diagnostic testing lab, Sonora Quest Laboratories, is teaming up with Ginkgo Bioworks, Inc. (“Ginkgo”), the organism company, a Boston-based biotechnology firm committed to supporting the fight against COVID-19, to provide pooled COVID-19 testing to K-12 school districts throughout Arizona. Continue reading
Indoor Drive-Thru Vaccination Site Opens at Dexcom in Mesa
“At Dexcom, our mission is to help improve the health of others, so when asked if we could provide our facility for an indoor mass-vaccination site, we didn’t hesitate,” said Jim Kasselmann, senior director of manufacturing in Mesa for Dexcom. “We are proud to manufacture our products in Mesa, and anytime we can help our local community, that is what we will do.”Continue reading
Regenesis Biomedical Introduces the New Provant Infinity
Scottsdale, Arizona based, Regenesis Biomedical, Inc. has launch the new Provant® Infinity system that is available purchase for home use when prescribed by a health professional. Outcomes with Provant Therapy are documented in journal articles, white papers, and case reports. Provant relieves pain in several post-operative conditions, including orthopaedic surgery, joint replacement, amputation, rotator cuff repair, back surgery, hernia repair, debridement, hand and foot surgeries, and neuropathy.Continue reading
Banner Alzheimer’s Institute gets $27.5M NIH grant for genetic risk study
Banner Alzheimer’s Institute (BAI) has received a grant expected to total $27.5 million over five years from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to further investigate biological and cognitive changes preceding the onset of memory and thinking problems in people at different levels of genetic risk for Alzheimer’s disease. Led by researchers from Banner and Mayo Clinic in Arizona, the five-year grant will study healthy people with six forms of the apolipoprotein E (APOE) gene, the major genetic risk factor for Alzheimer’s disease, create a shared scientific resource of data and biological samples to support a wide range of future studies, and help to advance the understanding, treatment, and prevention of Alzheimer’s disease.Continue reading
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma
In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and durable responses1
Safety profile of Abecma is well-established and predictable including cytokine release syndrome and neurologic toxicities that are mostly low-grade with early onset and resolution1
BD to Invest $65 Million for Key Supply Chain Infrastructure in Tucson, Arizona to Increase Resiliency of U.S. Medical Device Supply
TUCSON, Ariz., April 1, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona that will be a hub for the company’s supply chain, serving as a final-stage manufacturing and sterilization center.